By inhibiting β-catenin pharmacologically, it is possible to increase the number of dendritic cells (DCs), upregulate CCL4, and promote the infiltration of CD8+ T cells in various tumor models, including CRC, thereby reactivating anti-tumor immune responses (59–61). The gene discussed is CD8A; the disease is neoplasm.